Safety and efficacy outcomes in heavily and non-heavily pretreated patients with recurrent ovarian cancer (ROC) after single-agent trabectedin treatment: pooled analysis of phase II trials

被引：0
|
作者：
Kurzeder, C. [1 ]
Sehouli, J. [2 ]
Brugger, W. [3 ]
Zintl, P. [4 ]
De la Riba, M., I [4 ]
Kreienberg, R. [5 ]
机构：
[1] Kliniken Essen Mitte, Essen, Germany
[2] Charite, D-13353 Berlin, Germany
[3] Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany
[4] PharmaMar SA, Colmenar Viejo, Spain
[5] Univ Ulm Klinikum, Ulm, Germany
来源：
ONKOLOGIE | 2011年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：222 / 223
页数：2
相关论文
共 50 条
  • [1] Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment - Pooled Analysis of Phase II Trials
    Colombo, N.
    Del Campo, J. M.
    Sehouli, J.
    Sessa, C.
    Bidzinski, M.
    Nieto, A.
    Jiao, J.
    Kurzeder, C.
    Boman, K.
    Gonzalez-Martin, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S528 - S529
  • [2] Efficacy and safety outcomes in heavily pretreated patients (pts) with relapsed ovarian cancer (ROC) after single-agent trabectedin.
    Salutari, Vanda
    Ferrandina, Gabriella
    Vincenzi, Bruno
    Marinaccio, Marco
    Naglieri, Emanuele
    Loizzi, Vera
    Carpano, Silvia
    Lorusso, Domenica
    De Vincenzo, Rosa Pasqualina
    Grazia, Distefano Maria
    Amadio, Giulia
    Tonini, Giuseppe
    Scambia, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer (ROC).
    Boumedien, Feriel
    Adam, Jean-Philippe
    Akkour, Khalid
    LeTarte, Nathalie
    Provencher, Diane M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer
    Adam, Jean-Philippe
    Boumedien, Feriel
    Letarte, Nathalie
    Provencher, Diane
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 47 - 53
  • [5] Phase II trial of trabectedin (T) in heavily pretreated recurrent ovarian cancer (ROC) patients.
    Lorusso, D.
    Malaguti, P.
    Masciullo, V.
    Mainenti, S.
    di Legge, A.
    Ludovisi, M.
    Pesce, A.
    Mascilini, F.
    Fusco, E.
    Scambia, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] TRABECTEDIN AS SINGLE-AGENT IN HEAVILY PRETREATED PATIENTS WITH RELAPSED OVARIAN CANCER (ROC): RESULTS FROM A RETROSPECTIVE STUDY
    Salutari, V.
    Ferrandina, G.
    Vincenzi, B.
    Marinaccio, M.
    Naglieri, E.
    Loizzi, V.
    Carpano, S.
    Lorusso, D.
    Masciullo, V.
    Scarciglia, M. L.
    Amadio, G.
    Tonini, G.
    Scambia, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [7] Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer
    Watanabe, Yoh
    Koike, Eiji
    Nakai, Hidekatsu
    Etoh, Tomomaro
    Hoshiai, Hiroshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (04) : 345 - 348
  • [8] Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer
    Yoh Watanabe
    Eiji Koike
    Hidekatsu Nakai
    Tomomaro Etoh
    Hiroshi Hoshiai
    International Journal of Clinical Oncology, 2008, 13 : 345 - 348
  • [9] Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma
    Piura, B
    Meirovitz, M
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2005, 26 (04) : 386 - 390
  • [10] Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer
    Ardavanis, AS
    Ioannidis, GN
    Orphanos, GS
    Rigatos, GA
    ANTICANCER RESEARCH, 2006, 26 (2B) : 1669 - 1672
12345